AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01038687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03287076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Injection
Description: 5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
Study NCT03580161 — intervention group
Intervention type: OTHER
Intervention: 18-F FDG PET/CT dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
Study NCT03580161 — intervention group
Intervention type: OTHER
Intervention: Ga-68 PSMA PET/CT dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
Study NCT03580161 — intervention group
Intervention type: OTHER
Intervention: 68-Ga Dotatate PET/CT dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
Study NCT03580161 — intervention group
Intervention type: OTHER
Intervention: 99mTc Pertechnetate Thyroid dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
Study NCT03580161 — intervention group
Intervention type: OTHER
Intervention: 99mTc DMSA(III) Renal dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
Study NCT03580161 — intervention group
Intervention type: OTHER
Intervention: 99mTc MAG3 Renal dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
Study NCT03580161 — intervention group
Intervention type: OTHER
Intervention: 99mTc MDP/HDP Bone dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
Study NCT00324974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole microgranules suspension
Description: Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks.
Study NCT00324974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
Study NCT00369343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
Description: DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
Study NCT00369343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily (QD), tablet form, treatment period up to 8 weeks
Study NCT03489343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
Study NCT04610710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation
Description: Operation for deep infiltrating endometriosis
Study NCT04610710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fertility treatment
Description: In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)
Study NCT03143101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist trivalent (2015-2016)
Description: 0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
Study NCT03143101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist Quadrivalent (2015-2016)
Description: 0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
Study NCT03143101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist Quadrivalent (2017-2018)
Description: 0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
Study NCT04538469 — intervention group
Intervention type: OTHER
Intervention: COVID visitation restrictions
Description: Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
Study NCT02773095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novartis Access
Description: Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
Study NCT02047370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm stretching
Description: The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
Study NCT02047370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same therapist, patient position and duration of the technique, but using disconnected ultrasound
Study NCT01057667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid po, 24 weeks
Study NCT01057667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin [Copegus]
Description: 1000mg or 1200mg po daily
Study NCT01057667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin [Copegus]
Description: 1000mg or 1200mg po daily
Study NCT01057667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180mcg sc weekly
Study NCT01057667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180mcg sc weekly
Study NCT03155555 — intervention group
Intervention type: OTHER
Intervention: Measurement of aortic and carotid Doppler peak systolic velocity variation
Description: Aortic peak systolic velocity variation to be measured by echocardiography from apical five chamber and suprasternal windows alongwith carotid peak systolic velocity variation by Doppler ultrasound simultaneously at intermittent time points intermittently.
Study NCT02412202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Monitoring of pulmonary oedema induced by weaning from mechanical ventilation
Study NCT02631317 — intervention group
Intervention type: BEHAVIORAL
Intervention: Advance hospital notification by EMS
Description: Advance hospital notification by EMS
Study NCT02631317 — intervention group
Intervention type: BEHAVIORAL
Intervention: stroke team notification
Description: stroke team notification
Study NCT02631317 — intervention group
Intervention type: BEHAVIORAL
Intervention: key performance indicators feedback form
Description: a key performance indicators real-time feedback form as continuing quality improvement
Study NCT02631317 — intervention group
Intervention type: BEHAVIORAL
Intervention: standard informed consent procedures
Description: standard informed consent procedures with public poster of thrombolysis
Study NCT02631317 — intervention group
Intervention type: BEHAVIORAL
Intervention: performance of thrombolysis at CT-room
Description: performance of thrombolysis at CT-room or emergency room
Study NCT01409187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
Study NCT01409187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon
Description: 5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
Study NCT01409187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (Aldesleukin)
Description: 9 million IU/m\^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
Study NCT01028404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1952
Description: Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
Study NCT01028404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
Study NCT01028404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
Study NCT01028404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1952
Description: Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
Study NCT01028404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
Study NCT01028404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
Study NCT03340038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-ICU Specialty ward
Study NCT02247739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor
Study NCT02247739 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03218371 — intervention group
Intervention type: PROCEDURE
Intervention: chandelier-assisted peripheral vitrectomy under air
Description: chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
Study NCT04571736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: access to the internet information platform
Description: This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
Study NCT04028414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Weight Bearing
Description: Patients will be instruction to weight bear as tolerated while in a boot.
Study NCT00991289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ)
Description: 500 mg twice daily, taken orally with food
Study NCT00991289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (PEG)
Description: 180 micrograms via subcutaneous injection once weekly
Study NCT00991289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
Study NCT01655719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT01051817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: infusion 10 mg/Kg
Study NCT01051817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infusion
Study NCT04501484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-guided Focused Ultrasound VIM Thalamotomy
Description: Ablation of contralateral VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel)
Study NCT02571062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Study NCT00550797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPI ASM8
Description: Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
Study NCT00550797 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
Study NCT01792102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib and Dexamethasone
Description: Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m\^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m\^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16.
Study NCT04069676 — intervention group
Intervention type: OTHER
Intervention: EEG
Description: EEG, ECG and EDR record during a behavioral task
Study NCT02183012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen extrudate
Study NCT02183012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen lysinate
Study NCT02183012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT00237692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Behavioral intervention with Home BP Telemonitoring
Description: Nurse-administered behavior intervention
Study NCT00237692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Medication Management with Home BP Telemonitoring
Description: Nurse administer medication management according to hypertension decision support
Study NCT00237692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Combined intervention with Home BP Telemonitoring
Description: Combination of the nurse administered tailored behavioral \& medication management
Study NCT00289094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Rotating Platform (RP) Cruciate Retaining Knee System
Study NCT00289094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Fixed Cruciate Retaining Knee System
Study NCT03113968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electroconvulsive therapy (ECT)
Description: ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
Study NCT03113968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
Study NCT00992641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental diet
Description: Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
Study NCT00992641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Diet based on the information of the current dietary intake and food consumption in Nordic countries.
Study NCT02214342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
Study NCT02362893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Observed Therapy
Description: Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
Study NCT04293523 — intervention group
Intervention type: DRUG
Intervention: ELOCTA
Description: Extended half-life factor VIII product
Study NCT04807881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keynatinib
Description: All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is > 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
Study NCT03393039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Affect Task
Description: fMRI stress task
Study NCT00792909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 1 dose
Study NCT00792909 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 2 doses
Study NCT03503110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrocorticography with electrostimulation
Description: The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
Study NCT03503110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dRMI
Description: The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
Study NCT00385918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat Training
Description: The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
Study NCT00385918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home stretching then Lokomat training
Description: Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
Study NCT01899820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether lumefantrine
Description: Artemether 20mg Lumefantrine 120mg
Study NCT01899820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin piperaquine
Description: Dihydroartemisinin 20mg Piperaquine 160mg
Study NCT02580253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized Chemotherapy
Description: Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
Study NCT02580253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Oxaliplatin,Fluorouracil
Study NCT01386931 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-guided FNA performed with on-site Cytopathologist
Description: Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
Study NCT01386931 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-guided FNA performed without on-site Cytopathologist
Description: In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).